H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on BerGenBio AS (BRRGF) yesterday and set a price target of NOK66.00. The company’s shares closed last Monday at $3.30.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 27.6% and a 55.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BerGenBio AS with a $6.77 average price target.
See today’s analyst top recommended stocks >>
Based on BerGenBio AS’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $67.28 million. In comparison, last year the company had a GAAP net loss of $52.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
